Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis - PubMed
a day ago
- #FcRn blockers
- #generalized myasthenia gravis
- #indirect treatment comparison
- Nipocalimab, efgartigimod, and rozanolixizumab are FcRn blockers approved for treating generalized myasthenia gravis (gMG).
- Indirect treatment comparisons (ITCs) were conducted due to lack of direct trials comparing these therapies.
- Matching-adjusted indirect comparisons (MAICs) and Bucher ITCs were used to evaluate efficacy based on MG-ADL scores.
- Nipocalimab showed comparable onset of action at week 1 but greater sustained disease control vs. efgartigimod and rozanolixizumab in later weeks.
- Nipocalimab's cumulative effect (AUC) was significantly greater in MAICs and numerically greater in Bucher ITCs compared to other FcRn blockers.
- Sustained disease control is crucial for chronic diseases like gMG, and nipocalimab demonstrated consistent efficacy over time.
- The study was funded by Johnson & Johnson, with several authors having financial ties to pharmaceutical companies.